16:54 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Ascentage continues trend of large Chinese-led rounds

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised about $150 million in a series C round co-led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital and new investor Teng Yue Partners....
11:00 , Jul 17, 2018 |  BC Extra  |  Financial News

Ascentage continues trend of large Chinese-led rounds

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised about $150 million in a series C round co-led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital and new investor Teng Yue Partners....
21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
19:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Imbruvica, Venclexta combo leads to responses with no detectable MRD in Phase II for CLL

AbbVie Inc. (NYSE:ABBV) said 23 of the first 30 evaluable patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the Phase II CAPTIVATE (PCYC-1142) trial achieved a response with no...
18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

FDA grants regular approval to Venclexta

FDA granted regular approval to Venclexta venetoclax alone or in combination with Rituxan rituximab to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients with or without the 17p deletion who have...
21:11 , Jun 8, 2018 |  BC Extra  |  Company News

FDA grants regular approval to Venclexta

FDA granted regular approval to Venclexta venetoclax alone or in combination with Rituxan rituximab to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients with or without the 17p deletion who have...
18:11 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Ascentage reports Phase I data for APG-1252 in solid tumors

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) reported interim data from 13 evaluable patients with solid tumors, including six with small cell lung cancer (SCLC), in a Phase I trial showing that APG-1252 led...
16:15 , May 4, 2018 |  BC Week In Review  |  Financial News

Unity prices $85M IPO

Unity Biotechnology Inc. (NASDAQ:UBX) raised $85 million late May 2 through the sale of 5 million shares at $17 in an IPO underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. The price was at...
23:58 , May 2, 2018 |  BC Extra  |  Financial News

Unity prices $85M IPO

Unity Biotechnology Inc. (NASDAQ:UBX) raised $85 million late Wednesday through the sale of 5 million shares at $17 in an IPO underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. The price was at the...
13:42 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Unity proposes $85M IPO

On April 5, Unity Biotechnology Inc. (Brisbane, Calif.) filed to raise up to $85 million in an IPO on NASDAQ underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. Unity's lead candidates target senescent cells to...